New Chemo-Free Lymphoma Drug Offers Hope for Australian Patients

SINGAPORE – April 23, 2026 – Australian patients with a common and incurable form of blood cancer have been given new hope following the regulatory approval of a novel, chemotherapy-free treatment. The Therapeutic Goods Administration (TGA) has registered Minjuvi® (tafasitamab) for adults with relapsed or refractory follicular lymphoma, a decision that promises to shift the treatment paradigm for a challenging disease.

Announced by independent biopharmaceutical company Specialised Therapeutics (ST), the approval positions Minjuvi, when used in combination with rituximab and lenalidomide, as the first and only dual-targeted immunotherapy in Australia that attacks cancer cells on two fronts (CD19 and CD20) without relying on traditional chemotherapy. This milestone addresses a significant unmet need for the approximately 1,500 Australians diagnosed each year with follicular lymphoma, many of whom face a cycle of treatment and relapse.

A New Era for Follicular Lymphoma Treatment

Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma. While it is typically slow-growing, it is considered incurable. Patients often respond well to initial therapy, but the cancer almost invariably returns. With each relapse, the disease becomes more difficult to treat, and the periods of remission often shorten, leading to a poor long-term prognosis.

"While most patients with follicular lymphoma respond well to initial treatment and patients' prognosis has improved, around one in five will see their lymphoma return within two years, which is often linked to poorer long-term outcomes," said Professor Judith Trotman, a leading lymphoma specialist at Concord Repatriation General Hospital in Sydney. "For these patients, current therapies do not always deliver durable responses, highlighting the urgent need for evidence-based options that can meaningfully extend and improve their lives."

The approval of Minjuvi signifies a major step forward, offering a new mechanism of action for patients who have exhausted or are no longer candidates for conventional treatments. The ability to avoid the cumulative toxicities associated with chemotherapy is a significant benefit, potentially improving patients' quality of life during treatment.

"The TGA registration of Minjuvi marks an important new advance for patients with relapsed or refractory follicular lymphoma, bringing Australian clinical practice in line with accepted global standards of care," Professor Trotman added.

The Science Behind the Breakthrough

The TGA's decision was based on compelling results from the global Phase 3 inMIND clinical study, a large-scale trial that included 54 Australian patients across 12 local sites. The study was designed to evaluate the efficacy and safety of adding Minjuvi to the existing combination of rituximab and lenalidomide.

The results were both statistically significant and clinically meaningful. Patients who received the Minjuvi combination regimen experienced a median progression-free survival (PFS)—the length of time before their disease worsened—of 22.4 months. This was a substantial improvement over the 13.9 months seen in the control group. This translates to a 57% reduction in the risk of disease progression, relapse, or death for patients receiving Minjuvi.

Beyond its efficacy, the treatment was found to be generally well-tolerated. According to the study data, the safety profile was manageable, with the most common adverse reactions including respiratory tract infections, diarrhoea, rash, and fatigue. This profile is crucial for a patient population that may have already undergone several rounds of taxing therapies.

Carlo Montagner, Chief Executive Officer of Specialised Therapeutics, underscored the importance of this new option. "Follicular lymphoma is an incurable blood cancer and treatment options after relapse remain limited, with each recurrence more challenging to find effective treatments," he said. "We are extremely proud to bring the first and only chemotherapy-free treatment option to eligible Australians with relapsed or refractory follicular lymphoma, addressing a critical need for new therapies that may lower the risk of disease progression, relapse or death."

From Approval to Access: The Path Forward

While TGA registration is a landmark victory for patient care, it represents the first of two major hurdles in Australia. The next critical step is securing a listing on the Pharmaceutical Benefits Scheme (PBS), which would make the treatment affordable and widely accessible to the public.

Currently, Minjuvi is not listed on the PBS. Without this government subsidy, the cost of the innovative therapy would be prohibitive for most patients. Specialised Therapeutics has confirmed its intention to pursue reimbursement and is preparing to make its case to the Pharmaceutical Benefits Advisory Committee (PBAC).

The PBAC is tasked with evaluating the clinical effectiveness, safety, and cost-effectiveness of new medicines compared to existing treatments before recommending them for public funding. This rigorous process can be lengthy, but the strong data from the inMIND trial and the significant unmet need in this patient population provide a compelling foundation for the application.

"With TGA registration secured, we are committed to working with the Pharmaceutical Benefits Advisory Committee and Department of Health, Disability and Ageing to enable equitable access to Minjuvi for Australians with relapsed or refractory follicular lymphoma as soon as possible," Mr. Montagner stated.

A Strategic Win for Faster Access

The relatively swift approval of Minjuvi in Australia was facilitated by Project Orbis, an international program led by the U.S. Food and Drug Administration. This initiative allows for concurrent submission and review of promising cancer drugs among a coalition of global regulators, including Australia's TGA. By sharing expertise and workload, the program aims to get breakthrough therapies to patients faster.

This approval marks the ninth time since 2021 that Specialised Therapeutics has successfully used the Project Orbis pathway, demonstrating the company's proficiency in navigating complex international regulatory frameworks to bring novel treatments to the region. The company's partnership with Incyte, the global biopharmaceutical firm that developed tafasitamab, exemplifies a common strategy where local expertise is leveraged to ensure new medicines reach patients in markets like Australia, New Zealand, and Singapore.

For now, the TGA's green light provides Australian haematologists with a powerful new tool in their arsenal against a persistent and challenging cancer. The journey ahead will focus on ensuring that this promising medical advance translates into an accessible and affordable reality for every eligible patient.